Business
NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results With Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin & Total Revenue Growth of 163% to $9.1 Million for Fiscal Year 2025
Revenue Growth Fueled by Sales of the OneRF(R) Ablation System FDA 510(k) Clearance for OneRF(R) Trigeminal Nerve Ablation System with First Two Facial Pain Patients Successfully Treated Strengthened Balance Sheet Funds Growth Through Fiscal Year 202...
About this update from Neuroone Medical Technologies Corporation
[{"type":"image","caption":"","headline":"NeuroOne(R) to Report First Quarter Fiscal Year 2026 Financial Results on Tuesday, February 17 at 8:30 a.m. Eastern Time","size":{"original":{"width":140,"height":70,"url":"https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/61CM7UIIJoR34ZjwWwyL7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4","width":140,"height":70}}},{"type":"text","content":"Revenue Growth Fueled by Sales of the OneRF(R) Ablation System","length":62,"tagName":"p"},{"type":"text","content":"FDA 510(k) Clearance for OneRF(R) Trigeminal Nerve Ablation System with First Two Facial Pain Patients Successfully Treated","length":123,"tagName":"p"},{"type":"text","content":"Strengthened Balance Sheet Funds Growth Through Fiscal Year 2026","length":64,"tagName":"p"},{"type":"text","content":"Management to Host Conference Call Today at 8:30 a.m. Eastern Time","length":66,"tagName":"p"},{"type":"text","content":"EDEN PRAIRIE, MINN. - December 17, 2025 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the fourth quarter and fiscal year ended September 30, 2025.","length":379,"tagName":"p"},{"type":"text","content":"Fourth Quarter and Fiscal Year 2025 Financial Highlights","length":56,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Product revenue increased 163% to $9.1 million in fiscal year 2025, compared to $3.5 million in fiscal year 2024. Product revenue increased 907% to $2.7 million in Q4 fiscal 2025 versus Q4 fiscal 2024.","length":201,"tagName":"p"}]},{"val":[{"type":"text","content":"Product gross margin increased significantly to 56.5% for fiscal year 2025, compared to 31.3% for fiscal year 2024. Product gross margin was 55.8% in Q4 fiscal 2025, compared to 51.8% in Q4 fiscal 2024.","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses decreased 4.6% to $12.4 million in fiscal year 2025, compared to $13.0 million in fiscal year 2024, the second consecutive fiscal year that expenses have declined. Operating ex...